Literature DB >> 2867163

Deviating central hypotensive activity of urapidil in the cat.

P A van Zwieten, M J Mathy, M J Thoolen.   

Abstract

Urapidil, a novel antihypertensive drug, as well as possessing a peripheral alpha 1-adrenoceptor antagonistic effect, also has a significant degree of central hypotensive activity. When injected into the left vertebral artery of chloralose-anaesthetized cats the dose-dependent hypotensive effect of the drug was much stronger than after its systemic administration. Prior treatment, also via the vertebral artery, with various receptor antagonists (yohimbine, prazosin, diphenhydramine, metiamide, sulpiride, pirenzepine, R 56413, naloxone) did not antagonize the central hypotensive effect of urapidil administered subsequently. Accordingly, the central hypotensive action of urapidil is not mediated by central receptors of the following types: alpha 2- or alpha 1-adrenoceptors; H1- and H2-histamine; dopaminergic; muscarinic; 5-hydroxytryptamine; opiate. As such the mechanism of the central hypotensive action remains unexplained. It obviously deviates from that of classical centrally acting antihypertensive drugs like clonidine, guanfacine and alpha-methyldopa, which are agonists of central alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867163     DOI: 10.1111/j.2042-7158.1985.tb04973.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

Review 1.  The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

2.  Central and peripheral hypotensive activity of urapidil and its M1 and M2 metabolites in the cat.

Authors:  H Boss; R Boer; K D Beller; K H Sanders
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.

Authors:  B Tomlinson; J C Renondin; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Human pharmacology of urapidil.

Authors:  A M Shepherd
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Pharmacology of antihypertensive agents with multiple actions.

Authors:  P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors.

Authors:  A G Ramage
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

Review 7.  Clinical pharmacokinetics of urapidil.

Authors:  R Kirsten; K Nelson; V W Steinijans; K Zech; R Haerlin
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 8.  Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Drugs       Date:  1990       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.